Literature DB >> 16033422

Inhibition of p38 mitogen-activated protein kinase attenuates interleukin-1beta-induced thermal hyperalgesia and inducible nitric oxide synthase expression in the spinal cord.

Chun-Sung Sung1, Zhi-Hong Wen, Wen-Kuei Chang, Kwok-Hon Chan, Shung-Tai Ho, Shen-Kou Tsai, Yi-Chen Chang, Chih-Shung Wong.   

Abstract

We have reported recently that intrathecal (i.t.) injection of interleukin-1beta (IL-1beta), at a dose of 100 ng, induces inducible nitric oxide synthase (iNOS) expression and nitric oxide (NO) production in the spinal cord and results in thermal hyperalgesia in rats. This study further examines the role of mitogen-activated protein kinase (MAPK) in i.t. IL-1beta-mediated iNOS-NO cascade in spinal nociceptive signal transduction. All rats were implanted with an i.t. catheter either with or without an additional microdialysis probe. Paw withdrawal latency to radiant heat is used to assess thermal hyperalgesia. The iNOS and MAPK protein expression in the spinal cord dorsal horn were examined by western blot. The [NO] in CSF dialysates were also measured. Intrathecal IL-1beta leads to a time-dependent up-regulation of phosphorylated p38 (p-p38) MAPK protein expression in the spinal cord 30-240 min following IL-1beta injection (i.t.). However, neither the phosphorylated extracellular signal-regulated kinase (p-ERK) nor phosphorylated c-Jun NH2-terminal kinase (p-JNK) was affected. The total amount of p38, ERK, and JNK MAPK proteins were not affected following IL-1beta injection. Intrathecal administration of either selective p38 MAPK, or JNK, or ERK inhibitor alone did not affect the thermal nociceptive threshold or iNOS protein expression in the spinal cord. However, pretreatment with a p38 MAPK inhibitor significantly reduced the IL-1beta-induced p-p38 MAPK expression by 38-49%, and nearly completely blocked the subsequent iNOS expression (reduction by 86.6%), NO production, and thermal hyperalgesia. In contrast, both ERK and JNK inhibitor pretreatments only partially (approximately 50%) inhibited the IL-1beta-induced iNOS expression in the spinal cord. Our results suggest that p38 MAPK plays a pivotal role in i.t. IL-1beta-induced spinal sensitization and nociceptive signal transduction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16033422     DOI: 10.1111/j.1471-4159.2005.03226.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  41 in total

1.  An IL-1 receptor antagonist blocks a morphine-induced attenuation of locomotor recovery after spinal cord injury.

Authors:  Michelle A Hook; Stephanie N Washburn; Georgina Moreno; Sarah A Woller; Denise Puga; Kuan H Lee; James W Grau
Journal:  Brain Behav Immun       Date:  2010-10-23       Impact factor: 7.217

2.  Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain.

Authors:  Yasuhiko Kawasaki; Zhen-Zhong Xu; Xiaoying Wang; Jong Yeon Park; Zhi-Ye Zhuang; Ping-Heng Tan; Yong-Jing Gao; Kristine Roy; Gabriel Corfas; Eng H Lo; Ru-Rong Ji
Journal:  Nat Med       Date:  2008-02-10       Impact factor: 53.440

3.  Interleukin-1 receptor antagonist ameliorates the pain hypersensitivity, spinal inflammation and oxidative stress induced by systemic lipopolysaccharide in neonatal rats.

Authors:  Cheng-Ta Hsieh; Yih-Jing Lee; Jonathan W Lee; Silu Lu; Michelle A Tucci; Xiaoli Dai; Norma Beatriz Ojeda; Hyun Joon Lee; Lir-Wan Fan; Lu-Tai Tien
Journal:  Neurochem Int       Date:  2020-01-25       Impact factor: 3.921

4.  Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine.

Authors:  Zhi-Ye Zhuang; Yasuhiko Kawasaki; Ping-Heng Tan; Yeong-Ray Wen; Jing Huang; Ru-Rong Ji
Journal:  Brain Behav Immun       Date:  2006-12-15       Impact factor: 7.217

5.  Differential involvement of trigeminal transition zone and laminated subnucleus caudalis in orofacial deep and cutaneous hyperalgesia: the effects of interleukin-10 and glial inhibitors.

Authors:  Kohei Shimizu; Wei Guo; Hu Wang; Shiping Zou; Stacey C LaGraize; Koichi Iwata; Feng Wei; Ronald Dubner; Ke Ren
Journal:  Mol Pain       Date:  2009-12-21       Impact factor: 3.395

6.  P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis.

Authors:  Kimberly K Brown; Sandra A Heitmeyer; Erin B Hookfin; Lily Hsieh; Maria Buchalova; Yetunde O Taiwo; Michael J Janusz
Journal:  J Inflamm (Lond)       Date:  2008-12-04       Impact factor: 4.981

7.  p38 mediates mechanical allodynia in a mouse model of type 2 diabetes.

Authors:  Hsinlin T Cheng; Jacqueline R Dauch; Sang Su Oh; John M Hayes; Yu Hong; Eva L Feldman
Journal:  Mol Pain       Date:  2010-05-19       Impact factor: 3.395

8.  Nitric oxide synthase modulates CFA-induced thermal hyperalgesia through cytokine regulation in mice.

Authors:  Yong Chen; Michael K Boettger; Andreas Reif; Angelika Schmitt; Nurcan Uçeyler; Claudia Sommer
Journal:  Mol Pain       Date:  2010-03-02       Impact factor: 3.395

9.  Inflammatory pain-induced signaling events following a conditional deletion of the N-methyl-D-aspartate receptor in spinal cord dorsal horn.

Authors:  H T Cheng; M Suzuki; D M Hegarty; Q Xu; A R Weyerbacher; S M South; M Ohata; C E Inturrisi
Journal:  Neuroscience       Date:  2008-06-19       Impact factor: 3.590

10.  Effect of interleukin-1beta on spinal cord nociceptive transmission of normal and monoarthritic rats after disruption of glial function.

Authors:  Luis Constandil; Alejandro Hernández; Teresa Pelissier; Osvaldo Arriagada; Karla Espinoza; Hector Burgos; Claudio Laurido
Journal:  Arthritis Res Ther       Date:  2009-07-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.